Countries North America
LakeShore Biopharma Gains NMPA Approval for Phase III Trial of Simplified Four-Dose Rabies Vaccine Regimen
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developin...
October 28, 2024 | News
Corvia Medical’s Atrial Shunt Demonstrates Long-Term Efficacy in Heart Failure Patients: Three-Year Trial Results Published
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced impressive three-year results from its REDUCE LAP-HF II ...
October 28, 2024 | News
EpiVax and CUBRC Secure $2M FDA Contract to Develop T Cell Assay Standards for Generic Drug Immunogenicity
EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the...
October 25, 2024 | News
Medera Advances HFpEF Gene Therapy to High-Dose Cohort After Promising Results
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year Heart failure with preserved ...
October 25, 2024 | News
Australia's Telix Pharmaceuticals Secures FDA Priority Review for Pixclara® (TLX101-CDx) Glioma Imaging Agent
Telix Pharmaceuticals announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...
October 24, 2024 | News
Illumina Introduces MiSeq™ i100 Series, Simplifying NGS with Room-Temperature Storage and Speed
Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers...
October 24, 2024 | News
RAPT Therapeutics Boosts Drug Development Efficiency with INTEGRA Biosciences’ Pipettes for Cancer and Inflammatory Disease Research
RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small...
October 23, 2024 | News
Recursion Doses First Patient in Phase 2 Trial of REC-3964, a Novel Non-Antibiotic Treatment for Recurrent C. difficile Infection
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a uni...
October 23, 2024 | News
GE HealthCare Launches AI-Powered CareIntellect for Oncology to Streamline Cancer Treatment Insights
Application goes beyond data aggregation to help clinicians quickly see a longitudinal view of their patient’s history, spotlighting disease ...
October 22, 2024 | News
Thermo Fisher’s Oncomine Dx Target Test Receives FDA Approval to Guide Treatment with Servier’s VORANIGO® for Grade 2 IDH-Mutant Glioma
Oncomine Dx Target Test to Identify Patients Eligible for Servier’s VORANIGO® (vorasidenib) tablet, the only FDA-approved treatment for Grade 2 I...
October 22, 2024 | News
Australia's Telix Pharmaceuticals Files for Nasdaq Listing to Expand U.S. Market Access
Telix Pharmaceuticals announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U....
October 21, 2024 | News
CSL Vifor and Travere Therapeutics Secure Swissmedic Approval for FILSPARI in Treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults w...
October 18, 2024 | News
Isolere Bio by Donaldson Introduces Research-Grade IsoTag™ AAV Reagent for Superior Viral Vector Purification
Isolere Bio by Donaldson, an innovative bioprocessing technology provider, proudly announces the availability of research-grade IsoTag™ AAV reagent, ...
October 18, 2024 | News
Innovent Biologics' Picankibart Achieves Primary Endpoint in Phase 2 Clinical Study for Ulcerative Colitis
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
October 17, 2024 | News
Most Read
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
